Holen Sie sich die Stockscreener-App
43.59
9.14%
3.65
Handel nachbörslich:
43.60
0.010
+0.02%
Schlusskurs vom Vortag:
$39.94
Offen:
$39.97
24-Stunden-Volumen:
4.26M
Relative Volume:
2.64
Marktkapitalisierung:
$5.86B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-14.34
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+8.98%
1M Leistung:
+27.79%
6M Leistung:
+25.66%
1J Leistung:
-3.43%
1-Tages-Spanne:
$39.86
$43.71
1-Wochen-Bereich:
$39.37
$43.71
52-Wochen-Spanne:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
43.59 | 5.86B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Global RNAi Technology Market: Opportunities in Targeted - openPR.com
Antisense Oligonucleotides Market is expected to reach US$ - openPR.com
Ionis announces leadership change as chief development officer plans retirement - Investing.com India
Ionis announces Dr. Richard Geary, chief development officer, to - GuruFocus
Ionis announces leadership change as chief development officer plans retirement By Investing.com - Investing.com South Africa
JP Morgan Maintains Neutral Rating, Raises Price Target for Ionis Pharmaceuticals (IONS) | IONS Stock News - GuruFocus
Analyst Expectations For Ionis Pharmaceuticals's Future - Benzinga
Ionis Pharmaceuticals (IONS) Announces Leadership Change in Development | IONS Stock News - GuruFocus
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Announces Dr Richard Geary, Chief Development Officer, To Retire - MarketScreener
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 - The Joplin Globe
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits - Quantisnow
JPMorgan Adjusts Ionis Pharmaceuticals (IONS) Price Target to $4 - GuruFocus
JPMorgan Adjusts Ionis Pharmaceuticals (IONS) Price Target to $48 | IONS Stock News - GuruFocus
Ionis doses first subject in Phase III trial of Angelman syndrome therapy - Yahoo Finance
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome | IONS Stock News - GuruFocus
Ionis begins phase 3 trial of Angelman syndrome treatment By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (IONS) Advances with Phase 3 REVEAL Study for Angelman Syndrome | IONS Stock News - GuruFocus
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome - Yahoo Finance
Ionis Pharmaceuticals reports annual meeting results - Investing.com Australia
Ionis Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Day 8 of Gains Streak for Ionis Pharmaceuticals Stock with 13% Return (vs. 5.1% YTD) [6/9/2025] - Trefis
Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Ionis Pharmaceuticals (NASDAQ:IONS) versus Akero Therapeutics (NASDAQ:AKRO) Financial Contrast - Defense World
Transcript : Ionis Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? - Yahoo Finance
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed - simplywall.st
Transthyretin Amyloid Cardiomyopathy Treatment Market Deep Research ReportPfizer, Ionis Pharmaceuticals - openPR.com
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Pharmaceuticals’ SWOT analysis: RNA therapeutics firm faces pivotal year for stock - Investing.com
Angioedema Treatment Market Insights and Forecast from 2025 - openPR.com
Hereditary Angioedema Drugs Market 2034: EMA, PDMA, FDA - openPR.com
D. E. Shaw & Co. Inc. Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis’ olezarsen shows new promise with strong Phase III results - The Pharma Letter
December 2027 Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis reports success in olezarsen trial for high triglycerides - Yahoo
Treatment-Resistant Hypertension Market: Epidemiology, - openPR.com
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from HC Wainwright - Defense World
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Transcript : Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 08 - marketscreener.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Janus Henderson Group PLC - Defense World
Ionis reports positive data from study of olezarsen for hypertriglyceridemia - Clinical Trials Arena
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Birchler Brian | EVP, Corp and Development Ops |
Apr 15 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
57,340 |
| Birchler Brian | EVP, Corp and Development Ops |
Apr 16 '25 |
Sale |
28.37 |
680 |
19,292 |
56,660 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 15 '25 |
Option Exercise |
0.00 |
12,226 |
0 |
14,215 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr |
Apr 16 '25 |
Sale |
28.36 |
3,016 |
85,534 |
11,199 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
10,837 |
0 |
35,854 |
| Baroldi Joseph | EVP, Chief Business Officer |
Apr 16 '25 |
Sale |
28.40 |
3,928 |
111,555 |
31,926 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):